GFM
AVBP icon

GF Fund Management’s ArriVent BioPharma AVBP Stock Holding History

GF Fund Management’s Portfolio AVBP Stock Details AVBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$21.2K Buy
919
+108
+13% +$2.44K ﹤0.01% 497
2025
Q4 		$16.3K Sell
811
-62
-7% -$1.29K ﹤0.01% 528
2025
Q3 		$16.1K Buy
873
+10
+1% +$196 ﹤0.01% 516
2025
Q2 		$18.8K Hold
863
– – ﹤0.01% 508
2025
Q1 		$16K Buy
863
+155
+22% +$3.79K ﹤0.01% 522
2024
Q4 		$18.9K Buy
+708
New +$20.3K ﹤0.01% 477

Other funds holding AVBP

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
IAM
Infinitum Asset Management Fort Lauderdale, Florida $801M AUM 8.83% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

GF Fund Management's AVBP Position: Q1 2026 in Review

GF Fund Management increased its ArriVent BioPharma (AVBP) stake by 13% in Q1 2026, buying an estimated $2.44K and bringing the position to 919 shares worth $21.2K. The position accounts for ﹤0.01% of the portfolio, ranked #497.

GF Fund Management first reported a position in AVBP in Q4 2024 and has held it in 6 quarters since. 139 funds tracked by Wall St. Rank hold AVBP as of Q1 2026.

  • GF Fund Management held 919 shares of ArriVent BioPharma worth $21.2K as of Q1 2026.
  • GF Fund Management bought 108 ArriVent BioPharma shares in Q1 2026, an estimated $2.44K.
  • ArriVent BioPharma made up ﹤0.01% of GF Fund Management's portfolio in Q1 2026, its #497 holding.
  • GF Fund Management first reported a position in ArriVent BioPharma in Q4 2024 and has held it in 6 quarters since.
  • 139 funds tracked by Wall St. Rank held ArriVent BioPharma as of Q1 2026.

Based on GF Fund Management's 13F filing for Q1 2026, filed 15 Apr 2026.